Find your next paid study

The Methodist Hospital Research InstituteNCT07820358

~$75 – $2,000

Actual pay is set by the research site.

Breast CancerEndometrial CancerOvarian Cancer+5 more

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 …

Terremoto Biosciences Inc.NCT07109726

Actual pay is set by the research site.

Phase 2

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisf…

AmyloidosisBasal Cell CarcinomaBiliary Tract Carcinoma+26 more

~$75 – $2,000

Phase 3

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a t…

Endometrial Cancer

Merck Sharp & Dohme LLCNCT06952504

~$50 – $2,100

Actual pay is set by the research site.

Observational

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia

To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Cente…

Endometrial CarcinomaObesityEIN+2 more

Dana-Farber Cancer InstituteNCT04839614

~$10 – $1,125

Actual pay is set by the research site.

Phase 2

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and…

Recurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more

Jonsson Comprehensive Cancer CenterNCT04469764

~$75 – $2,000

Actual pay is set by the research site.

Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaEndometrial Neoplasms+2 more

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evalua…

Eli Lilly and CompanyNCT07046923

~$150 – $4,500

Actual pay is set by the research site.

Observational

Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers (HERA Trial)

After surgery to remove the main endometrial and/or cervical tumor, most women receive radiation therapy. This study uses hypo-fractionated radiation therapy, …

Endometrial CancerCervical Cancer

Jonsson Comprehensive Cancer CenterNCT06538337

~$10 – $750

Actual pay is set by the research site.

Breast CancerOvarian CancerEndometrial Cancer+6 more

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (…

Regor Pharmaceuticals Inc.NCT07524322

Actual pay is set by the research site.

Solid Tumor, AdultRefractory CancerEndometrial Carcinoma (EC)+4 more

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies …

GV20 TherapeuticsNCT05669430

Actual pay is set by the research site.

Ovarian CancerBreast CancerEndometrial Cancer+3 more

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and …

NextCure, Inc.NCT06774963

Actual pay is set by the research site.

NSCLC (Non-small Cell Lung Cancer)HNSCCEndometrial+5 more

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Advanced Solid Tumors

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects…